AstraZeneca gets green light for £27.5bn Alexion acquisition

pharmafile | July 14, 2021 | News story | Research and Development  

AstraZeneca has been given the green light of its $39 billion buyout of US-based rare diseases business Alexion by the Competition and Markets Authority (CMA).

As a result, AstraZeneca expects to close the deal next on 21 July, with new shares issued to Alexion shareholders beginning trading in London, Stockholm, and New York the following day.

Marc Dunoyer, Executive Director and Chief Financial Officer, said: “We are very pleased to have secured this critical final clearance from the UK Competition and Markets Authority for the acquisition of Alexion.

“We look forward to the imminent closing of the transaction so that we may pursue our shared ambition to bring more innovative medicines to patients worldwide and begin AstraZeneca’s next chapter of growth.”

First announced in December last year, the deal is intended to bolster AstraZeneca’s immunology capabilities, by adding Alexion’s technology platforms.

Subject to completing the acquisition, a group focusing on rare diseases will be created named Alexion, AstraZeneca Rare Disease, and will be headquartered in Boston, US.

In addition, the Alexion shares will be de‐listed from the Nasdaq Stock Market.

A management shake-up at AstraZeneca following the completion of the merger is expected.

Lilly Subbotin

Related Content

No items found

Latest content